| Market Cap | 34.38M | P/E | - | EPS this Y | 62.00% | Ern Qtrly Grth | - |
| Income | -74.49M | Forward P/E | -1.03 | EPS next Y | 14.90% | 50D Avg Chg | -36.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -56.00% |
| Dividend | N/A | Price/Book | 4.05 | EPS next 5Y | - | 52W High Chg | -87.00% |
| Recommedations | 2.20 | Quick Ratio | 1.25 | Shares Outstanding | 9.97M | 52W Low Chg | 4.00% |
| Insider Own | 0.77% | ROA | -233.79% | Shares Float | 9.19M | Beta | 1.51 |
| Inst Own | 5.82% | ROE | -1,271.87% | Shares Shorted/Prior | 153.96K/182.95K | Price | 3.45 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 684,156 | Target Price | 16.00 |
| Oper. Margin | - | Earnings Date | Aug 13 | Volume | 629,030 | Change | 2.07% |
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.